Weekly cisplatin plus capecitabine in metastatic breast cancer patients heavily pretreated with both anthracycline and taxanes

Oncology

Volumn 69, Issue 5, 2005, Pages 408-413

  Donadio, M ^a   Ardine, M ^a   Berruti, A ^b   Beano, A ^a   Bottini, A ^c   Mistrangelo, M ^a   Bonardi, S ^c   Castiglione, F ^d   Generali, D ^c   Polimeni, M A ^a   Bretti, S ^e   Alabiso, O ^f   Bertetto, O ^a  

^a MOLINETTE HOSPITAL   (Italy)

^b SAN LUIGI GONZAGA HOSPITAL   (Italy)

^c CREMONA HOSPITAL   (Italy)

^d Ospedale S Lazzaro   (Italy)

^e Ospedale di Ivrea   (Italy)

^f MAGGIORE DELLA CARITÀ HOSPITAL   (Italy)

Author keywords

Anthracycline; Capecitabine; Cisplatin; Metastatic breast cancer; Taxane

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; FLUOROURACIL; GEMCITABINE; METHOTREXATE; MITOMYCIN C; NAVELBINE; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; DIARRHEA; DRUG ACTIVITY; DRUG RESPONSE; DRUG SAFETY; EVALUATION; FEMALE; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; LEUKOPENIA; LIVER TOXICITY; METASTASIS; NAUSEA; NEUROTOXICITY; NEUTROPENIA; POPULATION; PRIORITY JOURNAL; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TOXICITY; TREATMENT FAILURE;

ANTHRACYCLINES; ANTIGEN-PRESENTING CELLS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CISPLATIN; DENDRITIC CELLS; DEOXYCYTIDINE; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENES, REPORTER; GREEN FLUORESCENT PROTEINS; HLA-A ANTIGENS; HUMANS; IMMUNOTHERAPY; INTERFERON TYPE II; LEUKOCYTES, MONONUCLEAR; MICROSCOPY, FLUORESCENCE; NEOPLASM METASTASIS; REMISSION INDUCTION; RNA, MESSENGER; TAXOIDS; TIME FACTORS; TRANSCRIPTION, GENETIC; TREATMENT OUTCOME;

EID: 29144459111     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000089995     Document Type: Article

References (33)

1. Cardoso F, Di Leo A, Lohrisch C, et al: Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades? Ann Oncol 2002;13:197-207.
2. Bruzzi P, Del Mastro L, Sormani MP, Bastholt L, Danova M, Focan C, Fountzilas G, Paul J, Rosso R, Venturini M: Objective response to chemotherapy as a potential surrogate endpoint of survival in metastatic breast cancer patients. J Clin Oncol 2005;23:5117-5125.
3. Crown J, Dieras V, Kaufmann M, et al: Chemotherapy for metastatic breast cancer - report of a European expert panel. Lancet Oncol 2002;3:719-727.
4. Ragazzoni S, Pesce G, Marini G, et al: Low-dose continuous intravenous infusion of 5-fluorouracil for metastatic breast cancer. Ann Oncol 1996;7:807-813.
5. Berruti A, Sperone P, Bottini A, et al: Phase II study of vinorelbine with protracted fluorouracil infusion as a second- or third-line approach for advanced breast cancer patients previously treated with anthracyclines. J Clin Oncol 2000;18:3370-3377.
6. Lombardi D, Magri MD, Crivellari D, et al: Combination chemotherapy with navelbine and continuous infusion of 5-fluorouracil in metastatic, chemotherapy refractory breast cancer. Ann Oncol 2000;11:1041-1043.
7. Lokich JJ, Bothe A, Benotti P, et al: Complications and management of implanted venous access catheters. J Clin Oncol 1985;3:710-717.
8. Miwa M, Ura M, Nishida M, et al: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998;34:1274-1281.
9. Blum JL, Jones SE, Buzdar AU, et al: Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999;17:485-493.
10. Blum JL, Dieras V, Lo Russo PM, et al: Multicenter, phase II study of oral capecitabine in taxane-pretreated metastatic breast cancer patients. Cancer 2001;92:1759-1768.
11. Reichardt P, Von Minckwitz G, Thuss-Patience PC, et al: Multicenter phase II study of oral capecitabine (Xeloda) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 2003;14:1227-1233.
12. Fumoleu P, Largillier R, Clippe C, et al: Multicentre, phase II study evaluating monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer 2004;40:536-542.
13. Martin M: Platinum compounds in the treatment of advanced breast cancer. Clin Breast Cancer 2001;2:190-208.
14. Frasci G, D'Aiuto G, Comella P, et al: Cisplatin-epirubicin-paclitaxel weekly administration with G-CSF support in advanced breast cancer. A Southern Italy Cooperative Oncology Group (SICOG) phase II study. Breast Cancer Res Treat 2000;62:87-97.
15. Jagasia MH, Langer CJ, Johnson DH, et al: Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study. Clin Cancer Res 2001;7:68-73.
16. Ohe Y, Niho S, Kakinuma R, et al: A phase II study of cisplatin and docetaxel administered as three consecutive weekly infusions for advanced non-small-cell lung cancer in elderly patients. Ann Oncol 2004;15:45-50.
17. Berardi R, Porfiri E, Scartozzi M, et al: Elderly patients with advanced non-small cell lung cancer. A phase II study with weekly cisplatin and gemcitabine. Oncology 2003;65:198-203.
18. Scanlon KJ, Nee Dels C: Biochemical basis for cisplatinum and 5-fluorouracil synergism in human tumors (abstract). Proc Am Soc Clin Oncol 1986;5:291.
19. Spaeth D, Conroy T, Krakowski I, et al: Long-term continuous combination of cisplatin and 5-fluorouracil in advanced breast neoplasms. A retrospective study of 77 patients. Bull Cancer 1993;80:351-356.
20. Fernandez Hidalgo O, Gonzalez F, Gil A, et al: 120 hours simultaneous infusion of cisplatin and fluorouracil in metastatic breast cancer. Am J Clin Oncol 1989;12:397-401.
21. Gonzalez F, Anton-Aparicio L, Dy C, et al: 120 hours simultaneous infusion of cisplatin and fluorouracil in drug resistant metastatic breast cancer (abstract). Proc Am Soc Clin Oncol 1986;5:59.
22. Chauvergne J, Mauriac L, Durand M, et al: Relay chemotherapy using continuous perfusion of cisplatin and fluorouracil in advanced cancer of the breast. Analysis of a series of 50 cases. Rev Fr Gynecol Obstet 1990;85:211-219.
23. Kucuk O, Pandya KJ, Skeel RT, et al: Phase II study of cisplatin and 5-fluorouracil in previously treated metastatic breast cancer: an Eastern Cooperative Oncology Group study (PA 185). Breast Cancer Res Treat 1999;57:201-206.
24. Yamada Y, Aiba K, Horikosi N, et al: Pilot study of continuous low-dose 5-fluorouracil and cisplatin (FP regimen) for the treatment of metastatic breast cancer. Int J Clin Oncol 2000;5:18-21.
25. Fumoleau P, Bastit P, Horner D, et al: Phase II trial as 2nd line chemotherapy with 5-fluorouracil and cisplatin (5FU-CDDP) for advanced breast cancer. Bull Cancer 1990;77:805-810.
26. Palacio I, Buesa JM, Baron FJ, et al: Inefficiency of cisplatin plus 5-FU as second- or third-line treatment in advanced breast cancer. Ann Oncol 1991;2:521.
27. Strauss G, Schwartz J, Nickerson J, et al: Continuous infusion (CI) 5-fluorouracil (5-FU) with or without cisplatin as third-line therapy for metastatic breast cancer (abstract 153). Proc Am Soc Clin Oncol 1988;7:39.
28. Pivot X, Chamorey E, Guardiola E, et al: Phase I and pharmacokinetic study of the association of capecitabine-cisplatin in head and neck cancer patients. Ann Oncol 2003;14:1578-1586.
29. Kim TW, Kang YK, Ahn JH, et al: Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer. Ann Oncol 2002;13:1893-1898.
30. Kim TW, Chang HM, Kang HJ, et al: Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer. Ann Oncol 2003;14:1115-1120.
31. Miller AB, Hoogstroten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 1981;47:207-214.
32. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 1999;91:523-528.
33. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10.